Therapeutic strategies employed during the course of the disease according to the JAK2 617V>F mutational state
| . | Polycythemia vera, n = 323 . | Essential thrombocythemia, n = 639 . | |||
|---|---|---|---|---|---|
| Hetero . | Homo . | WT . | Hetero . | Homo . | |
| Patients, no. (%) | 219 (67.8) | 104 (32.2) | 257 (40.2) | 368 (57.6) | 14 (2.2) |
| Phlebotomy, no. (%) | 131 (60.1) | 57 (54.8) | 4 (1.6)* | 20 (5.5) | 1 (7.1) |
| Chemotherapy, no. (%) | 121 (55.5)* | 70 (67.3) | 116 (45.1) | 180 (49.1) | 10 (71.4) |
| . | Polycythemia vera, n = 323 . | Essential thrombocythemia, n = 639 . | |||
|---|---|---|---|---|---|
| Hetero . | Homo . | WT . | Hetero . | Homo . | |
| Patients, no. (%) | 219 (67.8) | 104 (32.2) | 257 (40.2) | 368 (57.6) | 14 (2.2) |
| Phlebotomy, no. (%) | 131 (60.1) | 57 (54.8) | 4 (1.6)* | 20 (5.5) | 1 (7.1) |
| Chemotherapy, no. (%) | 121 (55.5)* | 70 (67.3) | 116 (45.1) | 180 (49.1) | 10 (71.4) |
Phlebotomy and chemotherapy were employed as either single or combined therapeutic option(s) in the same patient; however, their combination has not been considered.
P < .05 in the comparison of homozygous patients to either wild-type (in case of ET) or heterozygous counterpart.